What are Mission Vision & Core Values of Amicus Therapeutics Company?

How does Amicus Therapeutics align science and patients in its strategy?

Amicus Therapeutics anchors long-term growth in a patient-first, high-science mission that guides R&D, commercialization and capital allocation. By mid-2025 the company is a profitable commercial biotech focused on rare diseases and durable shareholder value.

These principles translate into clear priorities: accelerate therapies for rare genetic disorders, sustain commercial execution, and foster stakeholder trust through data-driven decisions.

What are Mission Vision & Core Values of Amicus Therapeutics Company? Amicus Therapeutics Porter's Five Forces Analysis

Mission: To transform lives of patients and families affected by rare genetic disorders, focusing on high‑impact therapies for lysosomal storage disorders worldwide.

Patient-Centered Impact

Prioritizes patients, families and the rare disease community in drug development and access efforts.

Scientific Innovation

Advances proprietary platforms such as pharmacological chaperones and next‑gen ERTs to address unmet needs.

Global Reach

Drives worldwide availability; by 2025 Galafold reached over 40 countries.

Commercial Execution

Launched combination therapies for Pompe disease to improve outcomes for patients not fully helped by first‑generation treatments.

Value Proposition

Unique focus on oral and improved ERTs offers differentiated therapeutic options within the rare disease market.

Commitment to Access

Seeks to expand patient access through regulatory approvals, reimbursement strategies and global partnerships.

Mission statement exemplifies a global, patient-first purpose targeting rare genetic disorders with innovative modalities and measurable commercial reach.

Mission: Our mission is to transform the lives of people living with rare diseases.

Amicus Therapeutics mission and vision emphasize patient impact, scientific innovation and global access; core values include patient-centricity, integrity, collaboration and excellence in research and development. Read more on business model and revenue details in Revenue Streams & Business Model of Amicus Therapeutics.

The vision of Amicus Therapeutics is to be the leading global biotechnology company focused on rare diseases, delivering transformational, patient-first therapies and sustainable commercial growth.

Specialized Leadership

Focused on rare disease dominance with targeted R&D and commercial expertise across regions.

Patient Centricity

Prioritizes patient outcomes and access, integrating real-world evidence into development.

Scientific Rigor

Invests in precision biology and novel modalities to advance personalized treatments.

Global Reach

Expanding commercial footprint in North America, Europe and Asia‑Pacific to reach more patients.

Fiscal Discipline

Balances aggressive R&D with sustainability; projected 15-20% revenue growth in 2025 and sustained non‑GAAP profitability.

Collaborative Culture

Encourages cross‑functional teamwork and partnerships with patient groups and payers.

Amicus Therapeutics’ vision targets rare disease leadership through patient focus, scientific innovation, and disciplined growth, backed by a 2025 trajectory showing double‑digit revenue expansion and expanded global commercialization — see Growth Strategy of Amicus Therapeutics for more details.

Amicus Therapeutics core values—The Amicus Way—guide decisions from R&D to patient access, emphasizing patient-centricity, scientific rigor, and ethical business practices. These values shape corporate culture, operational priorities, and strategic choices across the organization.

Patients First

Patient needs drive trial design and product priorities, using Patient Advisory Boards to align endpoints with real-world function and quality of life.

Passion

A culture of commitment and high employee engagement supports faster innovation and contributes to industry-leading retention and productivity.

Courage

Willingness to pursue high-risk R&D underpins ventures like combination therapies for Pompe disease, challenging established treatment paradigms.

Integrity

Transparent pricing and patient assistance programs aim to reduce access barriers while building trust with payers and providers.

Read next: how Amicus Therapeutics mission and vision influence strategic decisions and pipeline priorities, including 2025 supply-chain and patient-access commitments.

Values: The Amicus Way comprises five pillars; Patients First centers trial design via Patient Advisory Boards; Passion fuels high retention and collaboration; Courage drives bold R&D like Pompe two-component programs; Integrity guides pricing and access policies; Excellence underpins manufacturing and regulatory standards. Brief History of Amicus Therapeutics

The mission and vision shape Amicus Therapeutics' strategic choices, directing resource allocation, market entry, and operational priorities to maximize patient impact now. These guiding statements are cited by leadership to justify program prioritization and financial pivots that align commercial focus with patient needs.

Mission, Vision & Core Values — Snapshot

Clear statements that prioritize patients, scientific rigor and sustainable growth guide daily decisions and long-term strategy.

• Mission: Transform patients' lives now through approved therapies and patient support
• Vision: Become a leading rare disease company delivering global access to therapies
• Core Values: Patient-centricity, scientific excellence, integrity, collaboration, and long-term sustainability
• Operationalized via measurable goals: patient starts, revenue, and cash-flow targets

Strategic Prioritization

The 2024–2025 pivot toward financial sustainability saw reprioritization from early-stage gene programs to commercialization of approved products.

Program Decisions

Decisions to divest or pause certain programs were guided by the mission to deliver therapies now, preserving capital for product launches and patient access.

Commercial Focus

Global commercialization of Galafold and launches of Pombiliti and Opfolda became central to achieving revenue and patient-reach targets.

Patient Engagement

Market entry is preceded by local patient advocacy engagement to align launches with patient needs and support services.

Metrics of Success

Key metrics include patient-on-therapy counts, revenue growth, and achieving positive cash flow; patient starts have shown steady double-digit increases through 2025.

Leadership Alignment

CEOs and executives reference the mission in earnings calls to connect patient-centric strategy with long-term value creation.

The mission and vision drive program choices, market expansion, and funding of patient services—read the next chapter on Core Improvements to Company's Mission and Vision to see proposed refinements and measurable targets.

Influence: The mission and vision are primary drivers of strategy; in 2024–2025 Amicus prioritized commercializing Galafold and launching Pombiliti + Opfolda over some early-stage gene programs to secure capital and deliver therapies now, guided by patient-centered goals, engagement with advocacy groups, steady double-digit patient-on-therapy growth through 2025, and a focus on positive cash flow—see Target Market of Amicus Therapeutics for related market context.

Four core improvements to Amicus Therapeutics' mission and vision focus on sharpening scientific scope, clarifying long-term goals, embedding equity, and strengthening ESG accountability. These changes align the company with 2025 biotech trends, investor expectations, and global patient access needs.

Specify Genetic Medicine and Advanced Modalities

Refine the mission to explicitly include commitments to genetic medicine, mRNA, and protein engineering so Amicus Therapeutics mission reflects leadership in next-generation therapeutic platforms and supports pipeline prioritization.

Elevate Vision Toward Curative Therapies

Transform the Amicus Therapeutics vision to state pursuit of durable or one-time curative treatments, positioning the company competitively as industry peers advance toward curative modalities and reshaping long-term R&D strategy.

Embed Global Health Equity in Core Values

Incorporate explicit commitments to affordability and access for low-and-middle-income countries within Amicus Therapeutics core values, aligning company values with global patient needs and ESG expectations from investors.

Formalize ESG Metrics and Transparency

Adopt measurable ESG targets tied to pipeline decisions and public reporting—linking Amicus Therapeutics company values to quantifiable goals such as access programs, emissions reductions, and diversity benchmarks to meet 2025 investor standards.

Improvements: While the mission and vision of Amicus are strong, there are opportunities for refinement to better align with the evolving 2025 biotech landscape; the current mission is broad and could explicitly commit to genetic medicine and advanced modalities like mRNA or protein engineering. As competitors move toward one-and-done curative therapies, Amicus could refine its vision to pursue cures rather than only transforming lives, and integrate sustainability and health equity into Amicus Therapeutics core values to meet modern ESG priorities and enhance global access; see Competitors Landscape of Amicus Therapeutics.